BUENA, N.J. , April 03, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00 a.m. ET on Wednesday, April 8, 2020 to discuss the 4 th quarter and 2019 full year financial results and

BUENA, N.J. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced a transition in leadership. Teligent has announced that Jason Grenfell-Gardner will be stepping down immediately

BUENA, N.J. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration ( FDA ) for its abbreviated

BUENA, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies Global Healthcare Conference . The Conference is taking place November 20-21, 2019 in London, UK .

BUENA, N.J. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2019 . Third Quarter 2019 Highlights Net revenues of $18.5 million for the

BUENA, N.J. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, announced they will hold a conference call at 4:30pm ET on Monday November 4 th , 2019 to discuss the 3 rd quarter 2019 financial results and business update.

BUENA, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey -based specialty generic pharmaceutical company, announced the pricing of $34,405,000 aggregate principal amount of its 7.0% Cash / 8.0% PIK Series B Senior Unsecured

BUENA, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced that it has filed a prior approval supplement (PAS) for ranitidine hydrochloride injection. This is the planned first injectable product to be

BUENA, N.J. , Oct. 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

BUENA, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Teligent Inc. (Nasdaq: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced that it has retained SVB Leerink as its financial advisor to assist with a strategic review of assets non-core to the Company’s long-term